Future Medicine Decision Guide
CagriSema UK: The Definitive Guide to Evidence, Availability, Risks & Alternatives
A current UK guide to CagriSema: how cagrilintide and semaglutide work together, Phase 3 evidence, regulatory status, likely UK pathway, safety, comparisons and alternatives.
CagriSema UK status: where things actually stand
CagriSema is not yet a routine UK prescription treatment.
As of 8 August 2026, CagriSema remains investigational in Europe and the UK. Novo Nordisk submitted it for obesity approval in the United States in December 2025, with a US regulatory decision expected later in 2026. The company has said the European regulatory pathway is still linked to further data from the REDEFINE 3 cardiovascular-outcomes programme.
So this is a future-medicine guide, not a buying guide. If somebody is advertising “CagriSema” as a normal UK treatment today, that is not the same as receiving an approved medicine through a standard regulated prescribing pathway.
What is CagriSema?
CagriSema is a fixed-dose combination being developed by Novo Nordisk. It brings together two medicines in one once-weekly injection:
Semaglutide
A long-acting GLP-1 receptor agonist — the same active ingredient used in Wegovy for weight management.
Cagrilintide
A long-acting amylin analogue designed to work on appetite and satiety through a different hormonal pathway.
The combination
The idea is to combine two complementary appetite-regulation pathways rather than simply pushing one pathway harder.
The principal Phase 3 obesity dose studied has combined cagrilintide 2.4 mg with semaglutide 2.4 mg once weekly.
What is amylin — and why does cagrilintide matter?
Amylin is a hormone normally released alongside insulin after eating. It helps signal fullness and can influence how quickly food leaves the stomach. Cagrilintide is a long-acting amylin analogue designed to reproduce some of those effects in a form suitable for weekly treatment.
This matters because most modern obesity medicines have focused heavily on GLP-1 and related incretin pathways. CagriSema adds a second, different satiety pathway through amylin.
Wegovy says “GLP-1”. Mounjaro says “GIP + GLP-1”. CagriSema says “GLP-1 + amylin”. Same broad objective — reduce appetite and improve metabolic control — but via a different combination of biological signals.
How does CagriSema work?
Semaglutide can reduce hunger, increase fullness and improve glucose-dependent insulin signalling. Cagrilintide adds amylin-receptor activity, which is also associated with satiety and reduced food intake.
The appeal is not that one ingredient is “stronger” than the other. The scientific question is whether combining them produces more clinically useful weight loss, glycaemic benefit or tolerability than either component alone.
That is exactly what the REDEFINE and REIMAGINE programmes are designed to test.
What did REDEFINE 1 show in obesity?
REDEFINE 1 was the first pivotal Phase 3 trial of CagriSema in adults with overweight or obesity without diabetes. It enrolled 3,417 participants and compared CagriSema with semaglutide 2.4 mg, cagrilintide 2.4 mg and placebo over 68 weeks.
| Treatment | Mean weight change at 68 weeks | Context |
|---|---|---|
| CagriSema 2.4/2.4 mg | 22.7% under the efficacy estimand | Largest average loss in the trial. |
| Semaglutide 2.4 mg | Lower than CagriSema | Established GLP-1 benchmark. |
| Cagrilintide 2.4 mg | Lower than CagriSema | Shows the contribution of the amylin component alone. |
| Placebo | 2.3% | Background comparison. |
More than 40% of participants receiving CagriSema achieved weight loss of at least 25% in the efficacy analysis.
Different estimands, adherence patterns, dose modifications and individual biology all change the result a person might experience in real life.
What does the diabetes evidence show?
CagriSema is also being studied in type 2 diabetes through the REIMAGINE programme. In REIMAGINE 2, Novo Nordisk reported that CagriSema 2.4/2.4 mg produced an average 14.2% weight reduction at 68 weeks under the efficacy estimand, compared with 10.2% for semaglutide 2.4 mg, while also producing a larger reduction in HbA1c.
That is relevant because people with type 2 diabetes often lose less weight on obesity medicines than people without diabetes. It also suggests the combination may have a role that extends beyond body weight alone.
The wider CagriSema Phase 3 programme
| Programme | What it studies | Why it matters |
|---|---|---|
| REDEFINE 1 | Obesity / overweight without diabetes | Pivotal obesity efficacy and safety. |
| REDEFINE 2 | Obesity / overweight with type 2 diabetes | Weight loss in a harder-to-treat population. |
| REDEFINE 3 | Cardiovascular outcomes | Tests whether benefits extend to major cardiovascular events and long-term safety. |
| REDEFINE 4 | CagriSema vs tirzepatide | Direct head-to-head evidence rather than comparing separate trials. |
| REDEFINE 9 | Lower maintenance doses | May clarify whether everybody needs the full dose long term. |
| REDEFINE 11 | Further weight-loss potential | Explores longer or different treatment strategies. |
| High-dose programme | Higher-dose CagriSema | Tests whether more effect is achievable while preserving tolerability. |
Novo Nordisk's 2026 materials indicate that REDEFINE 3 cardiovascular-outcome data remain important to the European regulatory pathway.
How much weight could CagriSema eventually help people lose?
The headline Phase 3 obesity number is around 22.7% average weight reduction at 68 weeks in participants who adhered to treatment under the efficacy estimand.
For context only, somebody starting at 20 stone would mathematically see 22.7% equal to about 4.5 stone. That is not a forecast for an individual person.
The important comparison is not just “is the average number big?” but:
- How many people achieve clinically meaningful thresholds?
- How many can tolerate treatment?
- How does it compare directly with tirzepatide?
- What happens after treatment stops?
- What is the long-term cardiovascular and safety profile?
- What dose is actually needed for maintenance?
Side effects and tolerability
Across CagriSema trials, gastrointestinal effects have been the main adverse-event category, consistent with incretin and amylin-based treatment. Nausea, vomiting, diarrhoea and constipation are all important practical considerations.
The flexible-dose design in REDEFINE 1 is worth noting because treatment was not simply “everybody must reach the maximum no matter what”. Dose modification and tolerability are part of how a real obesity medicine needs to work.
Long-term cardiovascular outcomes, maintenance-dose strategies and higher-dose studies are still adding to the safety and benefit picture.
We have mature Phase 3 weight-loss data. We do not yet have a final UK product label, UK contraindication list, UK titration schedule or UK long-term prescribing guidance because the medicine is not yet authorised here.
When could CagriSema become available in the UK?
There is no confirmed UK launch date we can responsibly publish today.
Novo Nordisk filed CagriSema for obesity approval in the United States in December 2025, with a US decision expected in Q4 2026. Company materials in June 2026 said the EU regulatory pathway for obesity and type 2 diabetes is pending REDEFINE 3 cardiovascular-outcomes data.
That means a UK pathway could differ in timing from the US. Even after regulatory approval, commercial launch timing and NHS availability are separate questions.
If somebody has turned “promising regulatory progress” into an exact UK launch date, they have probably filled in the blanks themselves.
Will CagriSema be available on the NHS?
There is currently no NHS CagriSema pathway because it is not an authorised UK treatment.
If it is approved in future, NHS use would depend on NICE assessment, cost-effectiveness, commissioning and any prioritisation rules. Mounjaro already demonstrates why regulatory approval and NHS availability are not the same thing.
So a future NHS decision will need to consider not only how much weight CagriSema can help people lose, but also outcomes, safety, comparative effectiveness, price and how it fits against existing treatments.
What will CagriSema cost privately?
No legitimate UK private retail price exists yet because there is no authorised UK CagriSema product.
Future pricing could be influenced by Wegovy, Mounjaro, dose requirements, competition, provider services and whether the combination is positioned as a premium treatment.
An unapproved online product is not the same thing as a regulated future medicine supplied through a qualified prescriber and registered pharmacy.
CagriSema vs Wegovy
| Feature | CagriSema | Wegovy |
|---|---|---|
| Active pathways | Amylin + GLP-1 | GLP-1 |
| Components | Cagrilintide + semaglutide | Semaglutide |
| UK status | Investigational | Authorised |
| Obesity Phase 3 headline | 22.7% mean weight loss in REDEFINE 1 efficacy analysis | Strong established obesity evidence and real-world use |
| Routine treatment today | No | Yes, if clinically appropriate |
CagriSema is essentially asking whether adding long-acting amylin activity to semaglutide can produce a meaningfully better clinical outcome than semaglutide alone. REDEFINE 1 suggests stronger weight loss, but availability, cost, long-term outcomes and tolerability still matter.
CagriSema vs Mounjaro
This is likely to become one of the most commercially and clinically important obesity-treatment comparisons.
| Feature | CagriSema | Mounjaro |
|---|---|---|
| Mechanism | Amylin + GLP-1 | GIP + GLP-1 |
| Company | Novo Nordisk | Eli Lilly |
| UK today | Not yet authorised | Authorised |
| Direct head-to-head | REDEFINE 4 has been designed to compare CagriSema directly with tirzepatide, which is far more useful than comparing separate headline trial numbers. | |
Until direct head-to-head results and regulatory decisions are available, declaring a winner is premature.
CagriSema vs Retatrutide
These two future medicines take very different routes.
- CagriSema: combines amylin with GLP-1.
- Retatrutide: combines GIP, GLP-1 and glucagon receptor activity.
Retatrutide has produced larger headline Phase 3 weight-loss percentages in some studies, while CagriSema builds on the very mature semaglutide platform and introduces amylin as a complementary pathway.
Neither is currently a routine UK prescribing option, and each still has important evidence and regulatory questions outstanding.
Should I wait for CagriSema?
If you need treatment now
Do not delay appropriate care solely to wait for a future medicine. Mounjaro, Wegovy, Orlistat, lifestyle support, NHS services and surgery already exist.
If you're doing well now
There is no prize for switching simply because something newer arrives. Reassess only if the new option solves a real problem for you.
If current treatment isn't enough
Speak to a clinician about current alternatives rather than self-sourcing an investigational product.
The sensible question is not “is CagriSema coming?” It is “would waiting materially improve my health decision compared with the options I can safely use now?”
What can I choose today instead?
| Option | Available now? | Why consider it? |
|---|---|---|
| Mounjaro | Yes | Strong current obesity evidence; dual GIP/GLP-1 pathway. |
| Wegovy | Yes | Semaglutide-based GLP-1 treatment with mature obesity evidence. |
| Orlistat | Yes | Non-incretin oral option. |
| Lifestyle-first | Yes | Free or low-cost, builds foundations needed with or without medication. |
| NHS specialist support | Yes for eligible people | Multidisciplinary route that may include medication or surgery. |
| Bariatric surgery | Yes for suitable people | Established, powerful intervention for severe obesity. |
| CagriSema | No routine UK treatment | Future option subject to regulatory approval. |
Questions you haven't thought to ask yet
- Will I need the full 2.4/2.4 mg dose long term?
- Could lower maintenance doses reduce cost or side effects?
- How will it compare directly with tirzepatide?
- Will cardiovascular-outcomes data change who should use it?
- Will the UK licence be narrower than expected?
- Will the NHS prioritise it differently from Mounjaro?
- Will I be able to switch from Wegovy without restarting titration?
- What happens if I tolerate semaglutide but not cagrilintide?
- Would a standalone amylin medicine suit some people better?
- How will long-term weight regain compare after stopping?
- Will amylin-related effects create different appetite or nausea patterns?
- Would the extra weight loss justify a higher private price?
CagriSema FAQs
Is CagriSema available in the UK?
No. As of 8 August 2026 it is not a routine authorised UK prescription treatment.
What is in CagriSema?
It combines cagrilintide, a long-acting amylin analogue, with semaglutide, a GLP-1 receptor agonist.
Is CagriSema just stronger Wegovy?
No. It contains semaglutide but adds a second active medicine, cagrilintide, acting through the amylin pathway.
How often is CagriSema injected?
The Phase 3 programme uses once-weekly subcutaneous injections.
How much weight was lost in REDEFINE 1?
Novo Nordisk reported 22.7% mean weight reduction at 68 weeks under the efficacy estimand.
Is CagriSema better than Mounjaro?
A direct head-to-head Phase 3 programme is intended to answer this more reliably than cross-trial comparisons.
Is it better than Wegovy?
REDEFINE 1 showed greater average weight loss than semaglutide 2.4 mg, but overall suitability also depends on safety, tolerability, approval and long-term outcomes.
Will CagriSema be on the NHS?
There is no current NHS pathway. Any future NHS use would depend on regulatory approval and NICE/commissioning decisions.
How much will it cost?
There is no approved UK retail price yet.
When will it launch in the UK?
There is no confirmed UK launch date.
Has CagriSema been filed anywhere?
Novo Nordisk filed for obesity approval in the US in December 2025.
What are the main side effects?
Gastrointestinal effects have been the main adverse-event category in trials.
Should I wait for CagriSema?
Not automatically. If your health requires treatment now, discuss currently authorised options with a clinician.
Can I buy CagriSema online now?
An online product is not equivalent to a future authorised CagriSema medicine. Do not assume authenticity, quality or medical supervision.
What is cagrilintide?
It is a long-acting amylin analogue being developed to enhance satiety and support weight management.
Shift Says
If you were our brother...
We'd absolutely keep CagriSema on the radar. The Phase 3 evidence is strong enough that this is clearly more than a speculative lab project.
But we would not delay sensible treatment now just because the next medicine might be better. And we certainly would not buy something labelled “CagriSema” from an unregulated website before there is an approved UK product.
When it eventually becomes a genuine option, the questions will be simple: does it work better for you, can you tolerate it, is the extra benefit worth the cost, and what is the long-term plan?
Printable decision summary
Before I make any decision around CagriSema...
- I understand it is not yet a routine UK treatment.
- I understand CagriSema combines semaglutide with cagrilintide.
- I know the headline 22.7% weight-loss figure is a trial average, not a promise.
- I know direct comparison with tirzepatide is more important than social-media scorecards.
- I understand European/UK regulatory timing is not the same as US filing.
- I have considered treatment options available today.
- I will not buy an unapproved online product simply because it uses the CagriSema name.
Sources & further reading
Because CagriSema is still developing, we prioritise primary trial registries, Novo Nordisk's formal clinical/investor disclosures and regulator materials. This page should be reviewed whenever major regulatory or Phase 3 information changes.
- Novo Nordisk – REIMAGINE 2 Phase 3 results
- Novo Nordisk – 2025 Annual Report: CagriSema / REDEFINE 1
- Novo Nordisk – Q2 2026 investor presentation
- Novo Nordisk – 2026 R&D investor presentation
- ClinicalTrials.gov – REDEFINE 1
- ClinicalTrials.gov – CagriSema vs semaglutide
- ClinicalTrials.gov – CagriSema vs tirzepatide
- EMA – Cagrilintide/semaglutide paediatric investigation plan
The Shift Programme is coming soon
You do not need to wait for future medicines to start making progress. If you'd like structured support when our programme is ready, tell us how we can reach out.
Register to Shift Some TimberPut it head-to-head
Want to see how this option stacks up against another future medicine — or against Mounjaro or Wegovy?
Open comparison checker